When does Annex XIV apply in Performance Studies, and what key documentation is needed for compliance?

6:27

In the European regulatory landscape, conducting performance studies for in vitro diagnostic (IVD) devices requires navigating complex procedures outlined by the In Vitro Diagnostic Medical Devices Regulation (IVDR) 2017/746. For studies involving surgically invasive procedures or interventional studies for example, compliance with Annex XIV is essential. Manufacturers must develop well-planned strategies to ensure compliance and secure market access, paying close attention to timing, documentation, and regulatory processes across different Member States.

Understanding When Annex XIV Applies

According to the IVDR, those performance studies that are in scope of Article 58(1), Article 58(2), or Article 70 need to be submitted or notified to the competent authority. In summary, performance studies must be submitted for authorization if they:

Involve surgically invasive sampling solely for the study’s purpose,
Are classified as interventional clinical performance studies under Article 2, point (46),
Require additional invasive procedures or introduce other risks to study subjects.

Studies involving companion diagnostics using only leftover samples or post-market performance follow-up (PMPF) studies that do not subject participants to additional risks may require only notification to the competent authority rather than full authorization.

Key Documentation for Compliance

A critical part of both Annex XIV compliance and broader performance study applications under the IVDR is the preparation of comprehensive documentation. This includes:

Application Form: Provides essential details about the device, study objectives, and methodology. This form is submitted to the relevant national authority and must be filled out with accuracy and completeness to avoid delays in approval.
Performance Study Plan (PSP): A detailed roadmap that outlines the study’s objectives, design, methodology, statistical analysis, and safety measures. The PSP must comply with Sections 2 and 3 of Annex XIII.
Investigator’s Brochure (IB): A comprehensive document that presents all clinical and non-clinical data on the IVD device, including design, performance, safety, and previous studies. It ensures that investigators have a thorough understanding of the device before conducting the study.
Informed Consent Forms (ICFs): These must comply with the General Data Protection Regulation (GDPR) and local ethical requirements, ensuring participants are fully informed of the study’s risks and benefits.
Supporting Documents: This includes a signed statement from the manufacturer verifying that the device meets General Safety and Performance Requirements (GSPR), ethics committee approvals, proof of insurance, and any other national requirements for ethical and safety considerations.

Ethics Committee and Regulatory Approvals

Performance studies under IVDR often require approval from both the Competent Authority and an Ethics Committee (EC). The EC evaluates ethical aspects, ensuring participant safety and the scientific validity of the study design. Manufacturers must submit comprehensive information to meet the specific requirements of each EC, which can vary across different Member States.

In addition to ethical approvals, pre-submission consultations with regulatory bodies can help manufacturers address potential issues early, ensuring a smoother submission and review process. These consultations are available in some Member States and should be used to clarify requirements and reduce the risk of delays.

Meeting Annex XIV Requirements

For studies falling under Annex XIV, manufacturers must adhere to a rigorous process outlined in Article 58 of the IVDR. This includes:

Filling out the application form thoroughly, providing clear and accurate information on the device, study objectives, and methodology.
Developing a detailed Performance Study Plan that aligns with regulatory and ethical standards, ensuring participant safety and scientific validity.
Submitting comprehensive supporting documents, including ethics approvals, proof of insurance, and consent forms. Ensuring that the Investigator’s Brochure is updated with the latest research findings and provides a clear overview of the device’s design and performance.
Engaging with regulatory authorities early to address any potential issues and streamline the approval process. Utilizing pre-submission consultations can help mitigate costly delays.

Planning Submission Timelines Across Member States

Submission timelines and processes vary across Member States, so manufacturers must plan accordingly:

Understand Local Requirements: Research each country’s submission procedures, which may require simultaneous or sequential submissions to ethics committees and competent authorities.
Coordinate Timelines: Develop a schedule that accounts for potential delays due to regulatory reviews or requests for additional information.
Track Submissions: Maintain a tracking system to monitor the progress of submissions across jurisdictions, ensuring deadlines are met without bottlenecks.

Staying Updated on Regulatory Changes

The regulatory landscape under IVDR is still evolving. It’s crucial for manufacturers to:

Monitor Regulatory Updates: Stay informed about changes to the IVDR, as well as shifts in the authorization and notification processes in different Member States.
Adapt Strategies Accordingly: Be prepared to update submission strategies and documentation as necessary to maintain compliance with new regulations.

Conclusion: Navigating Compliance Successfully

Annex XIV compliance and IVD performance study applications under the IVDR demand strategic planning, robust documentation, and a thorough understanding of national requirements. By following a structured approach—engaging early with regulatory bodies, preparing detailed documentation, and coordinating submission timelines—manufacturers can navigate this complex regulatory process more effectively. Focusing on participant safety, ethical standards, and ISO 20916 compliance will not only ensure successful study execution but also expedite market access for innovative IVD devices.